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A B S T R A C T
Background/Objective: Utility values are not usually assessed in clinical trials and do not
allow cost-utility analysis to be performed with the data collected. The aim of this study was
to derive relation functions so that Health Assessment Questionnaire – Disability Index
(HAQ-DI) scores could be used to estimate Health Utilities Index - 3 (HUI-3) and EQ-5D utility
values for patients with rheumatoid arthritis (RA).
Methods: An observational, cross-sectional, naturalistic, multicentre study was conducted.
A total of 244 patients aged 18 years or older, with RA according to American College of
Rheumatology diagnostic criteria, were recruited. Sociodemographic and clinical variables
were recorded and patients completed three generic HRQoL questionnaires: the HAQ-DI, the
HUI-3, and the EQ-5D. Two linear regression models were used to predict HUI-3 and EQ-5D
utility values as functions of HAQ-DI scores, age, and gender.
Results: Patient mean age was 57.8 years old (standard deviation [SD], 13.3 years); 75.8%
of the patients were women and 95.9% were white. Mean disease duration was 10.8 years
(SD, 9 years). Patient distribution according to HAQ-DI severity was as follows: HAQ-DI
0.5, 29%; 0.5  HAQ-DI  1.1, 28%; 1.1  HAQ-DI  1.6, 16%,1.6  HAQ-DI  2.1, 15%; and
HAQ-DI  2.1, 12%. HAQ-DI and EQ-5D mean scores were 1.02 (SD, 0.78) and 63.1 (SD,
20.3), respectively. Mean utility values for HUI-3 and time trade-off (TTO) were 0.75 (SD,
0.21) and 0.65 (SD, 0.3), respectively. The equations converting HAQ-DI scores to utilities
were HUI-3  0.9527 – (0.2018  HAQ-DI)  (R20.56), and TTO  0.9567 – (0.309 
HAQ-DI)  (R20.54). Error distribution was non-normal. Age and gender were found to
have no bearing on the utility functions.
Conclusions: HAQ-DI scores can be used to estimate HUI-3 and EQ-5D utility values for
patients with RA in data obtained from studies where utility values have not been collected.
Copyright © 2011, International Society for Pharmacoeconomics and Outcomes Research(ISPOR). Published by Elsevier Inc.
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193V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 9 2 – 2 0 0ntroduction
usculoskeletal diseases are the most frequent cause of inca-
acity in the world. The long-term care required by patients
ith these diseases is included among the most costly dis-
ases to treat [1]. The cost of care correlates directly to increas-
ng functional incapacity [2,3]. Rheumatoid arthritis (RA) is a
hronic progressive disease characterized by inflammation
nd joint destruction; it limits patient mobility, causes func-
ional deterioration, affects health-related quality of life
HRQoL), and increases morbidity and mortality [4]. Preva-
ence varies geographically, ranging from 0.45% in the south of
urope to 0.65% in the north and center of Europe and the
nited States [5].
Some treatments aim to slow down disease progression
ut a majority of therapies claim to alleviate symptoms such
nflammation, pain, stiffness, swollen joints, and fatigue [5].
RQoL measures reflect a subjective evaluation of the follow-
ng key dimensions: the physical dimension (pain and deteri-
ration of physical functioning), the psychological dimension
anxiety and depression), the intellectual or cognitive dimen-
ion (attention and memory), and the social dimension (self-
steem and interpersonal relationships) [6].
The economic impact of RA and corresponding treatments,
ue to limited health-care resources and increased pressure
o use these resources efficiently, is of growing concern. The
ost effectiveness of new treatments must be compared to
lready available alternatives. In order to assess treatment
ffectiveness, the use of quality-adjusted lifeyears (QALYs) in-
orporates measures of both quantity and quality of life, and
btains a utility value associated with each health state. Util-
ty values correspond to perfect or full health state (corre-
ponding to a value of (1) and death (0) as well as collecting
alues of health states worse than death. A utility value indi-
ates the weight that general population or patients with a
pecific disease gives to a specific health state. In chronic and
rogressive diseases with negative impact on HRQoL, such as
A, the use of cost-utility analysis in economical evaluations
acilitates the global assessment of disease progression and
he associated impact on HRQoL.
The use of QALYs to evaluate benefits, in terms of health, is
idely used and is recommended by agencies for the assess-
ent of health technologies such as the National Institute for
ealth and Clinical Excellence (NICE) [7]. Utility values can be
ssessed using direct methods (e.g., time trade-off [TTO] or
tandard gamble [SG]) or indirect methods based on prefer-
nce or utility values assigned to health states defined by ge-
eric HRQoL questionnaires (the EQ-5D and Health Utilities
ndex – 3 [HUI-3]). The use of direct methods is the best way to
btain utility values in any population, including RA patients
8]. Nevertheless, due to resource restrictions, patients’ bur-
en and complexity of these methods, direct methods are not
sually included in clinical trials. The Health Assessment
uestionnaire Disability Index (HAQ-DI), developed to as-
ess difficulty performing day-to-day activities, is widely
sed in clinical research and in conditions of standard clin-
cal practice by patients with RA [9]. Linking HAQ-DI scores
o utility values enables the prediction of health state utility palues for cost per QALY analysis in cases where no prefer-
nce-based measure has been included in the study. This
ill aid cost-utility analysis (one possible method of eco-
omic evaluation) using data obtained from clinical trials
nd other clinical studies.
Studies have been performed in other countries to relate
AQ-DI scores to utility that is measured by RA patient-com-
leted HRQoL questionnaires [10,11]. Utility values measured
y generic questionnaires should be obtained at the country
evel due to social and cultural variability. In a preference
tudy performed to compare EQ-5D utility values based on
TO method between the United Kingdom and Spain, it was
hown that UK raters ascribed greater importance to di-
ensions of pain/discomfort and anxiety/depression,
hereas Spanish raters placed more importance on func-
ional dimensions of mobility and self-care [12]. A recent study
xamined the effects of differences in national EQ-5D value
ets on absolute and marginal utilities of health states [13]. It
as reported that differences between the EQ-5D value sets
ere too great to be ignored. It was further reported that some
ifferences could reflect cultural dissimilarities between
ountries and that transferring utility values from one country
o another without any adjustment was not advisable. Differ-
nces between utility functions between countries should
lso be reflected in the corresponding relation function with
ther HRQoL questionnaires.
The aim of this study was to obtain a relation function
etween HAQ-DI scores and HUI-3 and EQ-5D questionnaire
tility values in a sample of Spanish patients, and compare
he obtained function with those obtained in previous studies
erformed in other countries.
ethods
tudy design
n observational, cross-sectional, naturalistic, multicenter
ational study was conducted. The investigators who partici-
ated in the study were rheumatology specialists working in
utpatient clinics in hospitals in Spain. A total of 14 specialists
based in outpatient clinics) recruited patients over a 2-month
eriod. Patients were included consecutively. Because the
tudy was cross-sectional, patients made a single visit to pro-
ide the necessary information. Physicians recorded sociode-
ographic and clinical data, and administered the question-
aires included in the case report form to the patients. In
rder to obtain the minimum acceptable number of patients
or each level of RA severity, each physician was required to
nclude at least one patient per level: 0HAQ-DI 0.5 (level
); 0.5  HAQ-DI  1.1 (level 2); 1.1  HAQ-DI  1.6 (level 3);
.6 HAQ-DI 2.1 (level 4); 2.1 HAQ-DI 2.6 (level 5); and
AQ-DI  2.6 (level 6). The study was approved by the ethical
ommittee of the hospital Virgen de la Macarena (Seville) and
ll the included patients were informed of the study charac-
eristics, their right not to participate in the study, and their
ight to withdraw from the study at any time. All patients
igned an informed consent to indicate their willingness to
articipate in the study.
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194 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 9 2 – 2 0 0valuation criteria
atients were included if they fulfilled all the inclusion cri-
eria: adult diagnosed with RA as per the diagnostic criteria
f the American College of Rheumatology [14] and signed
he informed consent form. Patients were excluded if they
et any exclusion criteria: a diagnosis of other rheumatic or
egenerative diseases, participation in a clinical trial, or the
nability to read and understand the questionnaires.
tudy variables
he information collected in the study was grouped into two
ategories:
Sociodemographic variables (age, gender, ethnic origins,
level of education, and occupational status) and clinical
variables (date of diagnosis, number of surgical interven-
tions, number of joints affected, family history of the dis-
ease, concomitant diseases, and previous and current
treatments received for RA).
HRQoL and health state variables: HRQoL data and health
state preference information were compiled in order to as-
sess the status of patients with RA.
X HAQ-DI: The HAQ-DI is a self-completed questionnaire
to assess the extent of the RA patient’s functional ability
that assesses outcomes in patients with a wide variety of
rheumatic diseases, including RA. The HAQ-DI contains
20 items distributed across eight dimensions (dress and
groom, arise, eat, walk, reach, grip, maintain hygiene,
and maintain daily activity). Each item is scored on a
scale from 0 to 3 (reflecting no difficulty to disability).
Some additional points are added to the sum of the
corresponding items to calculate the dimension
scores. For example, if the patient needs assistance
from another person or uses adapted tools, this is re-
garded as reflecting a higher disability level [9]. For
each dimension a disability score from 0 to 3 is ob-
tained. HAQ-DI scores were categorized in order to re-
flect the disease activity level: HAQ-DI  0.5 (level 1);
0.5  HAQ-DI  1.1 (level 2); 1.1  HAQ-DI  1.6 (level
3); 1.6  HAQ-DI  2.1 (level 4); 2.1  HAQ-DI  2.6
Table 1 – Values for the multi-attribute utility function of th
scales.
Vision Hearing Speech Ambulation
A1 b1 A2 b2 A3 b3 A4 b4
1 1.00 1 1.00 1 1.00 1 1.00
2 0.99 2 0.95 2 0.96 2 0.94
3 0.92 3 0.87 3 0.89 3 0.86
4 0.85 4 0.80 4 0.78 4 0.73
5 0.74 5 0.72 5 0.62 5 0.62
6 0.62 6 0.59 6 0.52
Source: Ruiz M et al.16
Utility function: UHUI3  (1.0078  b1  b2  b3  b4  b5  b6  b7 
HUI-3, Health Utilities Index - 3; PH-PITS, possible-worst possible hea(level 5); and HAQ-DI  2.6 (level 6). dX HUI-3: The HUI-3 questionnaire is composed of eight at-
tributes (vision, hearing, speech, ambulation, dexterity,
emotion, cognition, and pain). Each attribute has either
five or six response levels, reflecting normality to severe
deterioration. The attributes and levels combined describe
972,000 health states that can be transformed into a mea-
sure of preference or utility for the population [15]. Utility
measurement instruments reflect patient preferences for
each health state by means of a single score that summa-
rizes, on a scale from 0 to 1, the subject’s health state and
the population’s preference for this state. Scoring of the
HUI-3 Spanish version questionnaire was based on the
utility function and values depicted in Table 1 [16].
X The EQ-5D questionnaire is a standardized, generic in-
strument for describing and valuing health [17]. The
EQ-5D questionnaire consists of a five-dimensional
descriptive system and a visual analogue scale (EQ
VAS). The descriptive system defines health in terms of
five dimensions: mobility, self-care, usual activities,
pain or discomfort, and anxiety or depression. Each di-
mension is divided into three levels, indicating no prob-
lem (coded as 1), some or moderate problems (coded as
2), or extreme problems (coded as 3). Combinations of
these levels define a total of 243 health states. A health
state defined by the descriptive EQ-5D system can be
described by a five-digit number, each digit indicating
the score of the corresponding dimension. The EQ VAS
asks respondents to rate their perception of their overall
health on a vertical visual analogue scale with “best
imaginable health state” set at 100 and “worst imagin-
able health state” set at 0. Utility values corresponding to
each EQ-5D health state were obtained in different coun-
tries using TTO method based on general population val-
uations [18]. Scoring in the Spanish version of the EQ-5D
questionnaire was based on the utility function and val-
ues depicted in Table 2 [19].
tatistical analysis
AS version 9.1 for Windows (Chicago, IL, USA) was used to an-
lyze the data. A statistical significance of 0.05 was applied to all
he tests performed. Results were categorized according to RA
anish version of the HUI-3 simplified best PH-PITS
Dexterity Emotion Cognition Pain
A5 b5 A6 b6 A7 b7 A8 b8
1 1.00 1 1.00 1 1.00 1 1.00
2 0.95 2 0.99 2 0.91 2 0.95
3 0.86 3 0.74 3 0.95 3 0.89
4 0.74 4 0.56 4 0.80 4 0.77
5 0.62 5 0.35 5 0.69 5 0.64
6 0.49 6 0.62
0.0078.e Sp
b8) –isease activity level that was measured by the HAQ-DI.
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195V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 9 2 – 2 0 0A descriptive and comparative analysis of sociodemo-
raphic characteristics and HRQoL, assessed using the
Q-5D and the HUI-3 questionnaires, was performed ac-
ording to the disability level assessed using the HAQ-DI.
Q-5D results were analyzed by taking into account the per-
entage of patients with problems (scores of 2 or 3) and the
Q VAS. The chi-square test was used for comparisons of
ategorical variables between groups that were homoge-
ous in terms of degree of severity. Continuous variables
ere compared using the analysis of variance (ANOVA) test
r using non-parametric techniques if normality criteria
ere not satisfied.
The relationships between HAQ-DI and utility values de-
ned using the HUI-3 and EQ-5D questionnaires were ob-
ained using two linear regression models, including utility
alues as dependent or explained variables and HAQ-DI
cores, and age and gender as independent or explanatory
ariables. The Shapiro-Wilks test was used to test the normal
istribution of residuals for both equations.
esults
ociodemographic and clinical characteristics
he final study sample consisted of 247 patients with RA,
hree were considered ineligible for the analysis due to the
ailure to record HAQ-DI scores and 244 patients were con-
idered to be evaluable. The mean age of patients was 57.8
ears old (SD, 13.3), 75.8% were women, and 95.9% were
hite. In terms of education level, 46.7% had only primary
ducation, 27.5% secondary, and 16.4% had completed a
hird level education. One-third of the patients were active,
ne-third were homemakers, and 20.9% were retired
Table 3).
Mean HAQ-DI score for the included patients was 1.02
oints (SD, 0.78 points), which corresponds to a moderate
Table 2 – Coefficients and function for calculating the
TTO index for the EQ-5D.
EQ-5D variables EQ-5D utility
values
Constant — 0.0399
Mobility (MOB) 2 (some problems) 0.0957
3 (many problems) 0.4230
Self-care (SCR) 2 (some problems) 0.1341
3 (many problems) 0.3114
Daily activities (ACT) 2 (some problems) 0.0775
3 (many problems) 0.2017
Pain/discomfort (PND) 2 (some problems) 0.0830
3 (many problems) 0.2560
Anxiety/depression 2 (some problems) 0.0506
(AND) 3 (many problems) 0.1358
Presence of 3 in state
(ST3)
— 0.2855
Source: Badia X, et al.19
EQ-5D (utility function) 1 – 0.0399MOBTTO SCRTTO ACTTTO
PNDTTO ANDTTO ST3TTO.
TTO, time trade-off.egree of disability. In order to make category sizes more 3omogeneous, the two categories with the highest HAQ-DI
cores were grouped together, resulting in a patient distri-
ution according to HAQ-DI score as follows: 29% in Level 1,
8% in Level 2, 16% in Level 3, 15% in Level 4, and 12% in
evels 5-6.
The mean age at diagnosis of patients in the study was
pproximately 47 years, resulting in an average disease evo-
ution of approximately 11 years. At the time of the patient’s
isit with the physician, the mean number of affected joints
as 4 (SD, 4.7). A total of 14.8% of the patients had a family
istory of RA, 20.1% had been treated surgically for their dis-
ase (arthroplasty, 48%; synovectomy, 16%; and orthopedic
urgery, 16%), and 52.9% had concomitant diseases (19.3%, en-
ocrine or metabolic diseases). Only 25% of the patients had
eceived treatment with anti-tumor necrosis factor (anti-TNF)
gents prior to their current treatment (infliximab and etan-
rcept, 57.4% and 41.0%, respectively). A total of 98.8% patients
n the sample were receiving drugs or other therapy when
hey visited the rheumatologist (methotrexate, 56.4%; pred-
isone, 31.5%; leflunomide, 24.5%; deflazacort, 17.4%; etaner-
ept, 17.0%; and infliximab, 6.6%).
RQoL and health state
he mean EQ VAS score was 63.1 points (SD, 20.3 points) on a
cale of 0 to 100, with statistically significant differences ac-
ording to disability based on HAQ-DI (P 0.001). Patients with
ower HRQoL suffered from greater levels of disability. By di-
ension, 80.4% of the patients had pain or discomfort (maxi-
um score in 12.3% of cases), 53.2% had difficulty performing
aily activities, 44.2% had mobility problems, 39.6% experi-
nced anxiety or depression, and 35.3% had problems with
elf-care. Figure 1 presents this information by degree of se-
erity. The reported levels of problems for all EQ-5D dimen-
ions increased according to the level of RA severity. Statisti-
ally significant differences were seen for all dimensions (P 
.01). Major differences according to the level of RA severity
ere observed in all physical dimensions (mobility, self-care,
nd usual activities), and was collected by the HAQ-DI.
When the perceived health status for all five dimensions
f the EQ-5D were combined and analyzed, only 14.5% of
atients with RA in the study stated that they had no prob-
ems in any questionnaire dimension (health state 11111).
o patient with an HAQ-DI score of 2.1 or more reported this
ealth state.
The mean HUI-3 utility score was 0.75 points (SD, 0.21
oints), with statistically significant differences between
roups according to HAQ-DI (P  0.001), with utility values
ecreasing as disability increased (Table 4). The mean utility
alues based on the EQ-5D questionnaire were 0.65 (SD, 0.3);
tility values varied significantly in accordance with RA sever-
ty, which was measured by the HAQ-DI (P  0.001).
Both approaches (HUI-3 and the EQ-5D utilities) showed
he same decreasing trend for utility values with respect to
ncreasing degrees of severity. This resulted in similar values
or each HAQ-DI category. The scatterplots reflecting each
tility measure with respect to the HAQ-DI confirm the exis-
ence of a relationship between pairs of variables (Figs. 2 and
).
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196 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 9 2 – 2 0 0In Figures 2 and 3, the relationships between the specific
AQ-DI scores and the generic HUI-3 and EQ-5D utility val-
es were analyzed using linear regression, with utility val-
es (HUI-3 or EQ-5D) as the dependent variables, and with
AQ-DI score and patient’s age and gender as independent
ariables. This analysis of the relationship between HAQ-
I scores and both HUI-3 and EQ-5D utilities revealed
Table 3 – Patient sociodemographic variables according to
HAQ-DI 
0.5
0.5 
HAQ-DI 1.1
n % n %
Age (P  0.065)
ND — 0.0 1 1.5
40 years 9 12.9 8 11.8
40–49 years 15 21.4 12 17.7
50–59 years 22 31.4 19 27.9
60–69 years 17 24.3 17 25.0
70 years 7 10.0 11 16.2
Gender (P  0.006)
ND — 0.0 1 1.5
Female 45 64.3 48 70.6
Male 25 35.7 19 27.9
Ethnic origin (P  0.169)
ND — 0.0 1 1.5
White 70 100 62 91.2
Latin American — 0.0 5 7.4
Education (P  0.246)
UNK/NR 1 1.4 1 1.5
None 2 2.9 6 8.8
Primary 30 42.9 30 44.1
Secondary 20 28.6 20 29.4
Third level 17 24.3 11 16.2
Occupational status
(P  0.001)
UNK/NR — 0.0 1 1.5
Unemployed — 0.0 1 1.5
Homemaker 16 22.9 22 32.4
Retired 13 18.6 14 20.6
Active 36 51.4 21 30.9
Sick leave — 0.0 1 1.5
Disability 4 5.7 8 11.8
Other 1 1.4 — 0.0
Total 70 100 68 100
HAQ, Health Assessment Questionnaire; ND, not determined; UNK/N
ig. 1 – Patients with problems for each dimension in EQ-5D
rthritis assessed by the Health Assessment Questionnaire Disahat patient age and gender had no bearing on utility
unction. The Shapiro-Wilks test ruled out the possibility
f a normal distribution of residuals for both equations
Table 5).
The equations to calculate utilities equivalent to the HUI-3
nd EQ-5D questionnaires from HAQ-DI scores for patients
ith RA are as follows:
rity of rheumatoid arthritis assessed by the HAQ-DI.
1.1 
-DI 1.6
1.6 
HAQ-DI 2.1
HAQ-DI 2.1 Total
% n % n % n %
0.0 — 0.0 — 0.0 1 0.4
7.5 2 5.4 — 0.0 22 9.0
22.5 3 8.1 4 13.8 43 17.6
30.0 10 27.0 7 24.1 70 28.7
20.0 9 24.3 5 17.2 56 23.0
20.0 13 35.1 13 44.8 52 21.3
0.0 1 2.7 — 0.0 2 0.8
92.5 31 83.8 24 82.8 185 75.8
7.5 5 13.5 5 17.2 57 23.4
0.0 — 0.0 — 0.0 1 0.4
97.5 36 97.3 27 93.1 234 95.9
2.5 1 2.7 2 6.9 9 3.7
0.0 — 0.0 — 0.0 2 0.8
5.0 5 13.5 6 20.7 21 8.6
60.0 16 43.2 14 48.3 114 46.7
27.5 10 27.0 6 20.7 67 27.5
7.5 6 16.2 3 10.3 40 16.4
0.0 — 0.0 — 0.0 1 0.4
0.0 — 0.0 2 6.9 3 1.2
45.0 11 29.7 9 31.0 76 31.2
10.0 11 29.7 9 31.0 51 20.9
37.5 9 24.3 1 3.5 82 33.6
2.5 — 0.0 1 3.5 3 1.2
2.5 6 16.2 7 24.1 26 10.7
2.5 — 0.0 — 0.0 2 0.8
100 37 100 29 100 244 100
known/no response.
criptive system according to severity of rheumatoidseve
HAQ
n
—
3
9
12
8
8
—
37
3
—
39
1
—
2
24
11
3
—
—
18
4
15
1
1
1
40des
bility Index (HAQ-DI).
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197V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 9 2 – 2 0 0UI-3 0.9527 0.2018HAQ-DI
Adjusted R2 0.56; Shapiro-Wilks P 0.001
Q-5D 0.9567 0.309HAQ-DI
Adjusted R2 0.54; Shapiro-Wilks P 0.001
The model designed to estimate HUI-3 utility values obtained
n R2 of 0.56, which means that HAQ-DI is able to explain 56% of
he HUI-3 scores variability. The predictive capacity of the model
s similar to that obtained with EQ-5D questionnaire (R20.54).
ased on previous equations, utility values based on HUI-3 are
btained by multiplying HAQ-DI score by 0.2018 and subtracting
he result from 0.9527.
iscussion
his study identified the relation function to use HAQ-DI
cores to obtain HUI-3 and EQ-5D utility values for Spanish
atients with RA, providing additional data on previous stud-
es performed in other countries. For economical evaluation
urposes the best approach is the inclusion of direct or indi-
ect methods to obtain utility values in clinical trials. Never-
Table 4 – Descriptive statistics for HUI-3 and EQ-5D utility
by the HAQ-DI.
HAQ-DI 
0.5
0.5  HAQ-DI 
1.1
1
HUI-3 (P  0.001)
Mean 0.91 0.80
SD 0.08 0.15
Min. 0.61 0.23
Median 0.93 0.83
Max. 1.00 1.00
Valid n 62 56
EQ-5D (P  0.001)
Mean 0.87 0.74
SD 0.14 0.19
Min. 0.28 0.19
Median 0.88 0.78
Max. 1.00 1.00
Valid n 68 66
HAQ-DI, Health Assessment Questionnaire Disability Index; HUI-3, H
ig. 2 – Scatter plot between Health Assessment Questionn
tilities Index Mark 3 (HUI-3) utility.heless, due to different factors, most of the clinical trials do
ot include any preference measure.
In this case, relation functions enable the prediction of
ealth state utility values at global level, for use in cost per
ALY analysis when no preference-based measure has
een included in the study. Due to inter-country variations,
t is highly recommended that relation functions be used
nly in the countries in which they were derived. The rela-
ion function presented in this study reports the first func-
ions to obtain utility values from HAQ-DI scores based on
panish RA patients.
The sample of study patients presents a sociodemographic
nd clinical profile similar to that of the profile of patients
ncluded in previous studies. Compared to the EMECAR study
20], which is one of the most important and more recent RA
atient studies performed in Spain, the sample of patients
ncluded in the present study is slightly younger (with a mean
ge 4 years younger) and with a very slightly higher proportion
f women (75.8% vs. 71.3%). From a clinical point of view, both
amples are comparable in terms of time of disease evolution
nd age at diagnosis. In terms of HAQ-DI scores, patients in-
luded in the present study report a slightly lower disability
evel. The 244 patients evaluated in our study had a mean
s according to severity of rheumatoid arthritis assessed
HAQ-DI 
1.6
1.6  HAQ-DI 
2.1
HAQ-DI 
2.1
Total
0.75 0.58 0.45 0.75
0.14 0.20 0.20 0.21
0.44 0.22 0.16 0.16
0.80 0.58 0.42 0.83
0.95 0.90 0.87 1.00
31 34 23 206
0.62 0.42 0.17 0.65
0.21 0.30 0.42 0.33
0.06 0.24 0.57 0.57
0.65 0.52 0.11 0.74
1.00 1.00 0.79 1.00
39 35 27 235
Utilities Index Mark 3.
Disability Index (HAQ-DI) scores and HUI-3, Healthvalue
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roup reported a mean score of 1.6 points for a sample of 788
A patients in 2003. The difference in terms of severity scores
an be attributed to differences in the patient selection meth-
ds used. The EMECAR study sample was selected from a ran-
om sample of patients with RA registered in the center at any
ime. According to the main study objective, the selection pro-
ess was mainly focused on obtaining a minimum sample of
atients covering all the HAQ-DI levels and able to respond to
rotocol requirements (questionnaires).
Utility values for HUI-3 and EQ-5D used in the present study
o obtain HAQ-DI utility value are based on general population
ssessments, not on patients’ assessments. Although the ques-
ion about whether patient-rated utility values should be ranked
igher than the general population-rated value has been dis-
ussed in several forums, it is generally accepted that economi-
al evaluations of health interventions should be analyzed from
societal point of view. In the present study, HAQ-DI values
ated by patients themselves have been used to predict utility
alues from a social point of view. Cost-utility analysis is based
n health states assessed by the patients themselves, in order to
ollect self-perceived HRQoL to weight length of life. These states
re generally converted to utility values evaluated from a social
oint of view, facilitating comparison with other health inter-
entions that can be applicable to other conditions.
Mortimer and Segal [21] completed a systematic review
f algorithms for converting descriptive measures of health
tatus into QALY-weights. They concluded that, although
Fig. 3 – Scatterplot between Health Assessment Questionn
Table 5 – Functions obtained between HAQ-DI and utility v
Variable df Parameter
estimate
Estimators for regression function
coefficients for HUI-3  f (HAQ-DI)
Intercept 1 0.9527
HAQ-DI 1 0.2018
Estimators for regression function
coefficients for EQ-5D  f (HAQ-DI)
Intercept 1 0.9567
HAQ-DI 1 0.3090HAQ-DI, Health Assessment Questionnaire Disability Index; HUI-3, Healthhe techniques used are quite different, the sensitivity and
alidity of derived QALY-weights could be more dependent
n the coverage and sensitivity of measures and the disease
rea/patients’ group under evaluation than on the tech-
ique used in derivation [21]. In this sense an important
oint to be analyzed is the validity of the EQ-5D, HUI-3, and
AQ-DI questionnaires in RA patients. Both generic prefer-
nce questionnaires used in the present study (EQ-5D and
UI-3) have been widely used and validated in RA patient
opulations [22-24]. Based on a comparison of methods to
btain utility values, the EQ-5D showed a better association
ith RA outcome measures than the TTO [24]. Despite the
alidity of all three questionnaires in RA population, a ceil-
ng effect affected discriminant validity of the EQ-5D and
UI-3 questionnaires and revealed the high proportion of
atients with no problems in any dimensions. This ceiling
ffect could have had a negative impact on the adjustment
btained with the relation function to convert HAQ-DI
cores to utility values, due the low variability of scores
btained in a significant group of patients. HAQ-DI is a dis-
ase-specific questionnaire widely used and accepted to be
sed in RA patients to assess the disability level.
Another factor to be considered to understand the rela-
ion functions obtained is the difference in dimensions or
actors assessed by general HRQoL questionnaires and the
AQ-DI. HAQ-DI is a functional questionnaire and does not
ssess some HRQoL factors, for example, mental health or
ain, which are usually included in generic questionnaires
Disability Index (HAQ-DI) scores and EQ-5D utility values.
s assessed using the HUI-3 and EQ-5D.
E T for H0:
parameter0
Prob  |T| 95% confidence
limit
59 59.92 0.0001 0.9214 0.9841
25 16.10 0.0001 0.2265 0.1771
38 40.15 0.0001 0.9098 1.0037
87 16.46 0.0001 0.3460 0.2720airealue
S
0.01
0.01
0.02
0.01Utilities Index Mark 3; SE, standard error.
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199V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 9 2 – 2 0 0sed to obtain utility values. Differences in dimensions or
actors assessed by each kind of questionnaire probably
ave a relevant impact on goodness of fit. Nevertheless,
ach questionnaire was developed and validated to respond
o specific objectives.
The approach used in the present study and the relation
unctions obtained are consistent with previous studies re-
orted in the literature using the HUI-3 [10], and EQ-5D ques-
ionnaires [11]. An analysis of adalimumab trial data of almost
000 patients permitted transformation from HAQ-DI to HUI-3
HUI-3 utility 0.76 – 0.286HAQ-DI 0.056FEMALE), with an R2
easure of 0.49 [10]. Despite the inclusion of gender, the R2
btained in the referenced study was slightly lower than
hat obtained in the present study (0.56). The comparison of
he EQ-5D function with that reported previously is not di-
ectly due to the different methodological approaches used.
lthough the final HAQ-DI scores in the present study has
een used to obtain the relation function, in the referenced
tudy, the individual scores were used. The methodology
sed in the present study resulted in a really simple model
ith an acceptable R2 (0.54), only slightly lower than that
btained in the referenced study. The added value of the
tility equations calculated in our study is that they reflect
ultural differences in how patients with RA self-report
heir health state and utility [25]. This generates more ac-
urate estimates, given their grounding in studies with
amples of patients conforming to national, cultural, and
isease characteristics.
There are some limitations in the current study. First,
he sample of RA patients was selected by 14 rheumatolo-
ists throughout Spain in order to obtain a more represen-
ative sample of patients. The lower disability level pre-
ented by patients, in comparison with the EMECAR study,
uggests a possible bias to a healthy population of RA pa-
ients. This is probably due to the requirement to include at
east one patient per each HAQ-DI level and also due to
atient requirements (such as the completion of three ques-
ionnaires) in order to be included and complete the study.
econd, relation functions were obtained for the total sam-
le of patients. A separate sample of patients was not used
o validate the relation functions obtained, comparing esti-
ated with observed values. This approach was not used
ue to the limited number of patients included in the study.
urther research about the validity and goodness of fit of the
elation functions obtained would provide additional infor-
ation about the capacity to estimate utility values based
n HAQ-DI at the global and patient levels. Third, the study
as designed to be cross-sectional in order to focus on the
elationship between preference-based questionnaires and
he HAQ-DI. The follow-up of the study patients and a second
dministration of the study questionnaires would allow analysis
f the reliability of the obtained scores and the derived relation
unction, as well as detection of possible changes over time. This
dditional information derived from a prospective study has
een analyzed only in some previous studies to estimate rela-
ion functions. Further research into the reliability and sensi-
ivity to change the relation functions obtained would provide
dditional understanding of the strengths and weaknesses of
he relation functions.cknowledgment
he authors acknowledge the contribution of Carlos Polanco
n prior versions of this article.
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